Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2012, Article ID 404810, 8 pages
http://dx.doi.org/10.1155/2012/404810
Review Article

MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions

1Center for Orthopedic Research (COR), Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA
2Department of Orthopedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Received 8 December 2011; Accepted 9 January 2012

Academic Editor: Charles Scoggins

Copyright © 2012 Chandhanarat Chandhanayingyong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. P. Link, A. M. Goorin, and A. W. Miser, “The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity,” New England Journal of Medicine, vol. 314, no. 25, pp. 1600–1606, 1986. View at Google Scholar
  3. G. Bacci, A. Longhi, M. Versari, M. Mercuri, A. Briccoli, and P. Picci, “Prognostic factors for osteosarcoma of the extremity trerated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution,” Cancer, vol. 106, no. 5, pp. 1154–1161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. H. J. Mankin, F. J. Hornicek, A. E. Rosenberg, D. C. Harmon, and M. C. Gebhardt, “Survival data for 648 patients with osteosarcoma treated at one institution,” Clinical Orthopaedics and Related Research, no. 429, pp. 286–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Y. Lee, H. J. Mankin, G. Fondren et al., “Chondrosarcoma of bone: an assessment of outcome,” Journal of Bone and Joint Surgery A, vol. 81, no. 3, pp. 326–338, 1999. View at Google Scholar · View at Scopus
  6. F. Y. Lee, A. C. Onishi, and A. M. Hincker, “Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets,” Sarcoma, vol. 2011, Article ID 381564, 8 pages, 2011. View at Publisher · View at Google Scholar
  7. D. N. Dhanasekaran and G. L. Johnson, “MAPKs: function, regulation, role in cancer and therapeutic targeting,” Oncogene, vol. 26, no. 22, pp. 3097–3099, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. S. Dhillon, S. Hagan, O. Rath, and W. Kolch, “MAP kinase signalling pathways in cancer,” Oncogene, vol. 26, no. 22, pp. 3279–3290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-P. Bayley and P. Devilee, “The warburg effect in 2012,” Current Opinion in Oncology, vol. 24, no. 1, pp. 62–67, 2012. View at Publisher · View at Google Scholar
  10. E. M. Eves and M. R. Rosner, “MAP kinase regulation of the mitotic spindle checkpoint,” Methods in Molecular Biology, vol. 661, pp. 497–505, 2010. View at Google Scholar
  11. H. G. Lee, H. Minematsu, K. O. Kim et al., “Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells,” Biomaterials, vol. 32, no. 35, pp. 9197–9206, 2011. View at Publisher · View at Google Scholar
  12. A. Mielgo, L. Seguin, M. Huang et al., “A MEK-independent role for CRAF in mitosis and tumor progression,” Nature Medicine, vol. 17, pp. 1641–1645, 2011. View at Publisher · View at Google Scholar
  13. Q. Zeng, S. Li, D. B. Chepeha et al., “Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling,” Cancer Cell, vol. 8, no. 1, pp. 13–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. W. Seo, D. Lee, H. Minematsu et al., “Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis,” Bone, vol. 46, no. 3, pp. 695–702, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Google Scholar · View at Scopus
  16. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar
  17. L. M. McGlynn, T. Kirkegaard, J. Edwards et al., “Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients,” Clinical Cancer Research, vol. 15, no. 4, pp. 1487–1495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Atmaca, C. Pauligk, K. Steinmetz, H.-M. Altmannsberger, E. Jäger, and S.-E. Al-Batran, “Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer,” Oncology, vol. 80, no. 1-2, pp. 130–134, 2011. View at Publisher · View at Google Scholar
  19. C. E. Pelloski, E. Lin, L. Zhang et al., “Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma,” Clinical Cancer Research, vol. 12, no. 13, pp. 3935–3941, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. U. Banerji, D. R. Camidge, H. M. W. Verheul et al., “The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer,” Clinical Cancer Research, vol. 16, no. 5, pp. 1613–1623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. D. Hainsworth, C. L. Cebotaru, V. Kanarev et al., “A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens,” Journal of Thoracic Oncology, vol. 5, no. 10, pp. 1630–1636, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. B. H. O'Neil, L. W. Goff, J. S. W. Kauh et al., “Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 29, no. 17, pp. 2350–2356, 2011. View at Publisher · View at Google Scholar
  23. K. K. Unni, C. Y. Inwards, and D. C. Dahlin, Dahlin's Bone Tumors: General Aspects and Data on 10,165 Cases, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 9th edition, 2009.
  24. K. Noh, K.-O. Kim, N. R. Patel et al., “Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas,” Journal of Bone and Joint Surgery A, vol. 93, no. 8, pp. 723–732, 2011. View at Publisher · View at Google Scholar
  25. K. Sasaki, T. Hitora, O. Nakamura, R. Kono, and T. Yamamoto, “The role of MAPK pathway in bone and soft tissue tumors,” Anticancer Research, vol. 31, no. 2, pp. 549–553, 2011. View at Google Scholar
  26. Y. Yu, F. Luk, J.-L. Yang, and W. R. Walsh, “Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model,” Anticancer Research, vol. 31, no. 4, pp. 1147–1152, 2011. View at Google Scholar
  27. R. Yang, S. Piperdi, and R. Gorlick, “Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase Kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma,” Clinical Cancer Research, vol. 14, no. 20, pp. 6396–6404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Messerschmitt, A. N. Rettew, R. E. Brookover, R. M. Garcia, P. J. Getty, and E. M. Greenfield, “Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2168–2175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Shimo, S. Matsumura, S. Ibaragi et al., “Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells,” Journal of Cell Communication and Signaling, vol. 1, no. 2, pp. 103–111, 2007. View at Google Scholar
  30. C. Y. Huang, C. Y. Lee, M. Y. Chen et al., “Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-κB-dependent pathways,” Journal of Cellular Physiology, vol. 221, no. 1, pp. 204–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Anders Kolb, R. Gorlick, P. J. Houghton et al., “Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program,” Pediatric Blood and Cancer, vol. 50, no. 6, pp. 1190–1197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. A. Kolb, D. Kamara, W. Zhang et al., “R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts,” Pediatric Blood and Cancer, vol. 55, no. 1, pp. 67–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. A. W. Tolcher, J. Sarantopoulos, A. Patnaik et al., “Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5800–5807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Montagut and J. Settleman, “Targeting the RAF-MEK-ERK pathway in cancer therapy,” Cancer Letters, vol. 283, no. 2, pp. 125–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Pignochino, G. Grignani, G. Cavalloni et al., “Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways,” Molecular Cancer, vol. 8, article no. 118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. T. Keir, J. M. Maris, R. Lock et al., “Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program,” Pediatric Blood and Cancer, vol. 55, no. 6, pp. 1126–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Grignani, E. Palmerini, P. Dileo et al., “A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study,” Annals of Oncology, 2011. View at Google Scholar
  38. T. Yamamoto, T. Ohno, K. Wakahara et al., “Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 8, pp. 1125–1136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Widermann, E. Fox, C. Adamson et al., “Phase I study of sorafenib in children with refractory solid tumors: a Children's Oncology Group Phase I Consortium trial,” in Proceedings of the ASCO Annual Meeting, 2009.
  40. S. Pacey, M. J. Ratain, K. T. Flaherty et al., “Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial,” Investigational New Drugs, vol. 29, no. 3, pp. 481–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. R. G. Maki, D. R. D'Adamo, M. L. Keohan et al., “Phase II study of sorafenib in patients with metastatic or recurrent sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3133–3140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Abdeen, A. J. Chou, J. H. Healey et al., “Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma,” Cancer, vol. 115, no. 22, pp. 5243–5250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. G. DuBois, S. Shusterman, A. M. Ingle et al., “Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study,” Clinical Cancer Research, vol. 17, no. 15, pp. 5113–5122, 2011. View at Publisher · View at Google Scholar
  44. F. G. Barr and R. B. Womer, “Molecular diagnosis of Ewing family tumors too many fusions...?” Journal of Molecular Diagnostics, vol. 9, no. 4, pp. 437–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. O. Delattre, J. Zucman, B. Plougastel et al., “Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature, vol. 359, no. 6391, pp. 162–165, 1992. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Cironi, N. Riggi, P. Provero et al., “IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells,” PLoS One, vol. 3, no. 7, Article ID e2634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Benini, M. C. Manara, V. Cerisano et al., “Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects,” International Journal of Cancer, vol. 108, no. 3, pp. 358–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. R. E. Silvany, S. Eliazer, N. C. Wolff, and R. L. Ilaria, “Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation,” Oncogene, vol. 19, no. 39, pp. 4523–4530, 2000. View at Google Scholar · View at Scopus
  49. S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman, “The role of IGF-1R in pediatric malignancies,” Oncologist, vol. 14, no. 1, pp. 83–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. J. A. Toretsky, T. Kalebic, V. Blakesley, D. LeRoith, and L. J. Helman, “The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts,” Journal of Biological Chemistry, vol. 272, no. 49, pp. 30822–30827, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Zenali, P. L. Zhang, A. E. Bendel, and R. E. Brown, “Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors,” Annals of Clinical and Laboratory Science, vol. 39, no. 2, pp. 160–166, 2009. View at Google Scholar · View at Scopus
  52. R. T. Kurmasheva, L. Dudkin, C. Billups, L. V. Debelenko, C. L. Morton, and P. J. Houghton, “The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma,” Cancer Research, vol. 69, no. 19, pp. 7662–7671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Manara, L. Landuzzi, P. Nanni et al., “Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1322–1330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Subbiah, A. Naing, R. E. Brown et al., “Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures,” PLoS One, vol. 6, no. 4, article e18424, 2011. View at Publisher · View at Google Scholar
  55. R. Kurzrock, A. Patnaik, J. Aisner et al., “A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors,” Clinical Cancer Research, vol. 16, no. 8, pp. 2458–2465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Bond, M. L. Bernstein, A. Pappo et al., “A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children's oncology group study,” Pediatric Blood and Cancer, vol. 50, no. 2, pp. 254–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. V. Subbiah and P. Anderson, “Targeted therapy of Ewing's sarcoma,” Sarcoma, vol. 2011, Article ID 686985, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. S. C. Seong, T. Matsumura, F. Y. Lee, M. C. Whelan, Xiao Qing Li, and S. B. Trippel, “Insulin-like growth factor I regulation of swarm rat chondrosarcoma chondrocytes in culture,” Experimental Cell Research, vol. 211, no. 2, pp. 238–244, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Lu, X. Tang, W. Guo, T. Ren, and H. Zhao, “Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway,” Journal of Surgical Oncology, vol. 102, no. 7, pp. 821–826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Jiang, C. M. Dutton, W. N. Qi, J. A. Block, N. Garamszegi, and S. P. Scully, “siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line,” Journal of Cellular Physiology, vol. 202, no. 3, pp. 723–730, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Yuan, C. M. Dutton, and S. P. Scully, “RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion,” Journal of Orthopaedic Research, vol. 23, no. 6, pp. 1467–1474, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. J. Chen, Y. Y. Wei, H. T. Chen et al., “Osteopontin increases migration and MMP-9 up-regulation via αvβ3 integrin, FAK, ERK, and NF-κB-dependent pathway in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 221, no. 1, pp. 98–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. E. C. Seales, G. A. Jurado, B. A. Brunson, J. K. Wakefield, A. R. Frost, and S. L. Bellis, “Hypersialylation of β1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility,” Cancer Research, vol. 65, no. 11, pp. 4645–4652, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. E. S. Yao, H. Zhang, Y. Y. Chen et al., “Increased β1 integrin is associated with decreased survival in invasive breast cancer,” Cancer Research, vol. 67, no. 2, pp. 659–664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. T. H. Lai, Y. C. Fong, W. M. Fu, R. S. Yang, and C. H. Tang, “Stromal cell-derived factor-1 increase αvβ3 integrin expression and invasion in human chondrosarcoma cells,” Journal of Cellular Physiology, vol. 218, no. 2, pp. 334–342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. C. Fong, T. M. Li, C. M. Wu et al., “BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway,” Journal of Cellular Physiology, vol. 217, no. 3, pp. 846–855, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Y. Yeh, C. C. Chiao, W. Y. Kuo et al., “TGF-β1 increases motility and αvβ3 integrin up-regulation via PI3K, Akt and NF-κB-dependent pathway in human chondrosarcoma cells,” Biochemical Pharmacology, vol. 75, no. 6, pp. 1292–1301, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. C.-H. Hou, Y.-C. Chiang, Y.-C. Fong, and C.-H. Tang, “WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells,” Biochemical Pharmacology, vol. 81, no. 11, pp. 1286–1295, 2011. View at Publisher · View at Google Scholar
  70. D. J. Papachristou, G. J. Papachristou, O. A. Papaefthimiou, N. J. Agnantis, E. K. Basdra, and A. G. Papavassiliou, “The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF,” Histopathology, vol. 47, no. 6, pp. 565–574, 2005. View at Publisher · View at Google Scholar · View at Scopus